SCIENCE OF RNAi

Paradigm Advantages

 

 

Existing Paradigm
siRNA Paradigm
  Drugs/MOA Small molecules, MoAb/Antagonists siRNAs in a delivery vehicle/Silencing
  Targets Mainly extracellular targets (Abs) All targets
  Selectivity and
Potency
Usually low (small molecules) Highly selective and potent
  Time to lead ID
& Optimization
Long (several years) Short (few months)
  Risk Usually high (small molecules) Low (following POC of delivery vehicle)